BBI, Thanks for you answer here. After a little thought I decides to delete the post about Lovaza - as the data is rather thin' - when you dig a little - regarding Alzheimer's. Actually not about Lovaza (not mentioned anywhere) but about OTC Fish Oil general in the Article from the AZ site.
BBI, https://www.clinicaltrials.gov/ct2/show/NCT02719327?term=Vascepa&draw=2&rank=9 The BRAVE study should read out with positive results. Prior studies have shown that Icosapent ethyl had statistically significant effects on both the primary and secondary endpoints in BRAVE. This study is fairly invasive. Each patient will need to undergo 3 separate spinal taps.(unless there is another way to collect CSF.) The study also has a data monitoring committee. I would think that the committee would have halted the study if the data collected, to this point, wasn't positive. I don't know if this study would be enough to apply for an SNDA. FDA did recently lower the bar for Alzheimer's disease approvals. Sleven,
BBI, As you say - this is probably the most sufferings area of 'fighting decease' out there. Still researchers is in realty 'guessing' what will help/prevent the terrible decease.
But a lot of research is going on. An overview of where things stand right now can be found in link below:
Market Data 
Markets 
AI
